CollPlant Biotechnologies Ltd
No SEC Form 4 filings for $CLGN in the last 30 days.
See all $CLGN insider activity →CollPlant (CLGN) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing a prior deficiency matter. The company's shares met the criteria for ten consecutive days. CEO Yehiel Tal expressed commitment to advancing the company's technological and commercial roadmap, including developments in photonic computing and biotechnology.
CollPlant (CLGN) will host an investor webinar on September 17, 2026, to introduce its newly acquired subsidiary LightSolver, which focuses on photonic computing. The event will discuss LightSolver's technology, roadmap, and commercialization plans, marking CollPlant's diversification into advanced computing alongside its existing regenerative medicine and 3D bioprinting businesses.
CollPlant (CLGN) granted its Deputy CEO and CFO, Rotem Eran, 510,372 restricted share units (RSUs) on September 3, 2026. The RSUs vest over five years, with 30% vesting in 2027 and the remainder in equal installments. After a 1-for-10 reverse stock split, Eran's total holdings amount to 516,372 ordinary-share equivalents.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLGN (CollPlant Biotechnologies Ltd). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CLGN coverage spans mergers & acquisitions, corporate actions and financial news.
The compliance regain removes a delisting risk, likely supporting the stock price and reducing downside pressure.
The acquisition expands CollPlant into photonic computing, potentially diversifying revenue streams.
The grant increases insider ownership and may signal confidence, but the size is modest for a microcap.
The reverse split reduces share count and aims to meet Nasdaq bid‑price rules, while the LightSolver acquisition expands CollPlant into high‑performance computing.
The deal expands CollPlant into photonic computing, likely boosting long‑term growth prospects but may dilute focus on biotech.
AlphAI scores every news story that mentions CLGN with an AI model for sentiment and relevance, and aggregates insider trades from CollPlant Biotechnologies Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
CollPlant (CLGN) has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, closing a prior deficiency matter. The company's shares met the criteria for ten consecutive days. CEO Yehiel Tal expressed commitment to advancing the company's technological and commercial roadmap, including developments in photonic computing and biotechnology.
1 min readCollPlant (CLGN) will host an investor webinar on September 17, 2026, to introduce its newly acquired subsidiary LightSolver, which focuses on photonic computing. The event will discuss LightSolver's technology, roadmap, and commercialization plans, marking CollPlant's diversification into advanced computing alongside its existing regenerative medicine and 3D bioprinting businesses.
2 min readCollPlant (CLGN) granted its Deputy CEO and CFO, Rotem Eran, 510,372 restricted share units (RSUs) on September 3, 2026. The RSUs vest over five years, with 30% vesting in 2027 and the remainder in equal installments. After a 1-for-10 reverse stock split, Eran's total holdings amount to 516,372 ordinary-share equivalents.
1 min readCollPlant (CLGN) shares fell 6% after a 1-for-10 reverse split to comply with Nasdaq's price requirement. The company also completed its acquisition of LightSolver, entering high-performance computing, and appointed Dr. Ruti Ben Shlomi to its board. CLGN shares traded at $3.22 in premarket. The company focuses on regenerative medicine and now high-performance computing.
2 min readCollPlant (CLGN) appointed Dr. Ruti Ben Shlomi, CEO of LightSolver, to its board after acquiring LightSolver. Ben Shlomi brings expertise in photonic computing, aiming to commercialize LightSolver's Laser Processing Unit (LPU) technology. CollPlant is diversifying into high-performance computing while continuing its biotech focus.
1 min readCollPlant (CLGN) is acquiring LightSolver, a developer of photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address computational speed and energy challenges. The deal includes upfront shares, warrants, and milestone-based payments. LightSolver is working with partners like Boeing (BA) to validate its technology, targeting commercial availability by 2028.
2 min readCollPlant (CLGN) announced a 1-for-10 reverse share split, effective September 4, 2026, to comply with Nasdaq's minimum bid price requirement. Shareholders do not need to take action. The company focuses on regenerative medicine and 3D bioprinting.
2 min readU.S. stocks fell midday, with the Dow, Nasdaq, and S&P 500 down 0.64%, 0.40%, and 0.51% respectively. Energy shares rose 1.8%, while communication services dropped 1.9%. The Dallas Fed's manufacturing index surged to 11.6 in August. Notable movers: CLGN (+123%), ASND (+6%), TITN (+13%), FNGR (-39%), EIX (-23%), PCG (-20%). Oil gained 2.5% to $85.50, while gold fell 1.3% to $4,473.10. European and Asian markets were mixed.
2 min readCollPlant (Nasdaq: CLGN) is acquiring LightSolver, a company developing photonic computing technology. LightSolver's Laser Processing Unit (LPU) aims to address speed and energy limitations of semiconductor-based computing. The acquisition includes equity and milestone-based warrants. LightSolver is partnering with Boeing (NYSE: BA) and other global leaders for commercial validation. The deal is expected to close this week.
3 min readCollPlant (CLGN) agreed to acquire LightSolver, a developer of photonic computing technology. The deal includes 3.7M shares, 6.1M pre-funded warrants, and 224.1M milestone-based warrants. LightSolver's LPU™ targets high-intensity workloads, with Boeing (BA) as a partner. Closing is expected this week, pending shareholder approval.
2 min read
